NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3944 participants.

Also called NCT05638867

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,944 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05638867
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05638867. Randomized; single masking; primary purpose treatment. Start 2023-11-25 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
Condition
Acute Coronary Syndrome
Intervention (Drug)
Aspirin + Clopidogrel + Rivaroxaban
Intervention (Drug)
Aspirin + Clopidogrel
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct05638867
Content hash
507dc80807dce67e56ab7544f20bc87cf8e56933d4c20ea4f52995570373d658